Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claim 1 (currently amended): A method for the delivery of a phthalazine derivative to the retina of a subject afflicted with a retinal disease, comprising the topical ocular administration to a subject in need of treatment of an effective amount of an aqueous composition comprising a compound of formula (I) to treat retinal disease afflicting the subject, wherein formula (I) is



(I)

wherein

n is 0 to 2,

R is H or lower alkyl;

X is imino, oxa, or thia;

Y is aryl; and

Z is unsubstituted or substituted pyridyl,

an N-oxide thereof, wherein 1 or more N atoms carry an oxygen atom,

or a salt thereof, wherein the retinal disease is selected from the group consisting of macular edema, choroidal neovascularization, retinal neovascularization, exudative age related macular degeneration, proliferative diabetic retinopathy and ischemic retinopathy.

Claims 2-5 (cancelled)

Claim 6 (original): The method of claim 1 wherein said subject is a human.

Claim 7 (original): The method of claim 1,

wherein

n is 0 or 1;

R is H or lower alkyl;

X is imino, oxa or thia;

Y is phenyl, lower alkenyl, lower alkoxycarbonyl, lower alkylcarbamoyl, lower alkanoyl, phenyloxy, halogen-lower alkyloxy, lower alkoxycarbonyl, lower alkylmercapto, halogen-lower alkylmercapto, hydroxy-lower alkyl, lower alkylsulfonyl, phenylsulfonyl, halogen-lower alkylsulfonyl, dihydroxybora ($-B(OH)_2$), 2-methylpyrimidin-4-yl, oxazol-5-yl, 2-methyl-1,3-dioxolan-2-yl, 1H-pyrazol-3-yl, 1-methyl-pyrazol-3-yl, lower alkylenedioxy bound to two adjacent C-atoms, pyridyl, or 4-chloro-2-fluoroanilino, wherein said phenyl is unsubstituted or is substituted by one or two substituents independently of one another from the group comprising amino, lower alkanoylamino, halogen, lower alkyl, halogen-lower alkyl, hydroxy, lower alkoxy, phenyl-lower alkoxy and cyano; and

Z is 3- or 4-pyridyl, lower alkyl, halogen-lower alkyl, lower alkoxy or hydroxy, wherein said pyridyl is unsubstituted or is substituted by one or two substituents independently of one another from the group comprising halogen.

Claim 8 (original): The method of claim 1,

wherein

n is 0 or 1;

R is H;

X is imino;

Y is phenyl, lower alkanoylamino, halogen, lower alkyl, halogen-lower alkyl, hydroxy, lower alkoxy, phenyl-lower alkoxy or cyano, wherein said phenyl is unsubstituted or is substituted by one or two substituents independently of one another from the group comprising amino; and

Z is 4-pyridyl, lower alkyl, halogen-lower alkyl, hydroxy and lower alkoxy, wherein pyridyl is unsubstituted or is substituted by a substituent from the group consisting of halogen.

Claim 9 (original): The method of claim 1,

wherein

n is 0 or 1;

R is H;

X is imino;

Y is phenyl, lower alkyl, halogen-lower alkyl, hydroxy; lower alkoxy or cyano, wherein phenyl is unsubstituted or is substituted by one or two substituents independently of one another from halogen; and

Z is 4-pyridyl, lower alkyl, halogen-lower alkyl, hydroxy or lower alkoxy, wherein said pyridyl is substituted or unsubstituted by a halogen.

Claim 10 (original): The method of claim 1,

wherein

n is 0;

X is imino;

Y is phenyl, methyl, trifluoromethyl, hydroxy, cyano or methoxy, wherein said phenyl is substituted or unsubstituted by fluorine or chlorine; and

Z is 4-pyridyl, methyl, trifluoromethyl, hydroxy or methoxy, wherein said pyridyl is substituted or unsubstituted by fluorine or chlorine.

Claim 11 (original): The method of claim 1,

wherein

n is 0;

X is imino;

Y is phenyl, methyl, methoxy, cyano or trifluoromethyl, wherein said phenyl is substituted or unsubstituted by chlorine or fluorine; and

Z is 4-pyridyl or methyl, wherein said pyridyl is substituted or unsubstituted by chlorine or fluorine.

Claim 12 (currently amended): The method of claim 1, wherein said compound is selected from the group consisting of:

1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Methylanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Chloroanilino)-4-(4-pyridylmethyl)phthalazine;

1-Anilino-4-(4-pyridylmethyl)phthalazine;

1-Benzylamino-4-(4-pyridylmethyl)phthalazine;

1-(4-Methoxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Benzyloxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Methoxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(2-Methoxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Trifluoromethylanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Fluoroanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Hydroxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Hydroxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Aminoanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3,4-Dichloroanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Bromoanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Chloro-4-methoxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Cyanoanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Chloro-4-fluoroanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Methylanilino)-4-(4-pyridylmethyl)phthalazine; and

pharmaceutically acceptable salts thereof.

Claim 13 (currently amended): The method of claim 1, wherein said compound is [1-(3-Chloroanilino)-4-(4-pyridylmethyl)phthalazine] 1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine.

Claims 14-17 (cancelled)

Claim 18 (currently amended) A composition comprising a squeezable container suitable for dispensing drops of an aqueous solution, and further comprising disposed within said container an aqueous composition comprising water and a compound of formula (I) to treat retinal disease afflicting the subject, wherein formula (I) is



(I)

wherein

n is 0 to 2;

R is H or lower alkyl;

X is imino, oxa, or thia;

Y is aryl; and

Z is unsubstituted or substituted pyridyl,

an N-oxide thereof, wherein 1 or more N atoms carry an oxygen atom,

or a salt thereof, wherein the retinal disease is selected from the group consisting of macular edema, choroidal neovascularization, retinal neovascularization, exudative age related macular degeneration, proliferative diabetic retinopathy and ischemic retinopathy.

Claim 19 (currently amended):The composition of claim 18, wherein said compound is selected from the group consisting of:

1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine.

1-(4-Methylanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Chloroanilino)-4-(4-pyridylmethyl)phthalazine;

1-Anilino-4-(4-pyridylmethyl)phthalazine;

1-Benzylamino-4-(4-pyridylmethyl)phthalazine;

1-(4-Methoxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Benzyloxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Methoxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(2-Methoxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Trifluoromethylanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Fluoroanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Hydroxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Hydroxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Aminoanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3,4-Dichloroanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Bromoanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Chloro-4-methoxyanilino)-4-(4-pyridylmethyl)phthalazine;

1-(4-Cyanoanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Chloro-4-fluoroanilino)-4-(4-pyridylmethyl)phthalazine;

1-(3-Methylanilino)-4-(4-pyridylmethyl)phthalazine; and

pharmaceutically acceptable salts thereof.

Claim 20 (new): The composition of claim 19, wherein said compound is 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine.